Press Release: Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results

Dow Jones11-12

EsoGuard(R) now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume to start the fourth quarter

Conference call and webcast to be held today, November 12, at 8:30 AM EST

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update and reported financial results for the third quarter ended September 30, 2026.

Conference Call and Webcast

The webcast will take place on Thursday, November 12, 2026, at 8:30 AM EST and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days in the investor relations section of the Company's website at luciddx.com.

Business Highlights

"Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth."

"Our pursuit of EsoGuard's enormous clinical and commercial opportunity is now substantially less constrained by external factors," Dr. Aklog added. "Lucid's near-term growth now depends almost entirely on our team's commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint."

Highlights from the third quarter and recent weeks:

   -- Received first Medicare payments for the EsoGuard(R) Esophageal DNA 
      Test in October. Lucid began submitting claims in late September after 
      meeting with medical directors at Novitas, the Medicare Administrative 
      Contractor (MAC) with jurisdiction over Lucid's Texas laboratory, and 
      providing a clinical evidence dossier incorporating their feedback. Lucid 
      has consistently received payments on these claims at EsoGuard's 
      established Clinical Laboratory Fee Schedule rate of $1,938.01 per test. 
      This Medicare coverage through claim-by-claim adjudication is independent 
      of the pending MolDX Local Coverage Determination (LCD) reconsideration 
      for EsoGuard. 
 
   -- Immediately and aggressively repositioned commercial efforts to expand 
      EsoGuard testing among at-risk Medicare beneficiaries, representing 
      approximately half of the patients recommended for esophageal precancer 
      testing by professional society guidelines. 
 
   -- Performed 2,871 EsoGuard tests and recognized revenue of $1.2 million in 
      3Q26. October was a record month for EsoGuard test volume, with more than 
      1,800 tests. More than 50,000 EsoGuard tests have been performed since 
      launch. 
 
   -- Held a formal meeting with CMS leadership on the pending MolDX LCD 
      reconsideration for EsoGuard. The discussion reinforced Lucid's 
      confidence that the delay is attributable to an administrative backlog. 
      Lucid expects the draft LCD to be published as that backlog begins to 
      clear. 
 
   -- Continued to expand commercial coverage through the Concert EsoGuard 
      coverage policy, with a total of five Concert client health plans, 
      including the three previously reported, expected to have formally 
      adopted it by year-end. 
 
   -- Launched Lucid's first two U.S. Department of Veterans Affairs 
      (VA) programs, with a robust pipeline of additional VA centers behind 
      them. Lucid continues to expect the VA to be a meaningful long-term 
      contributor to its commercial activity and revenue. 
 
   -- Announced billing and coding milestones, including a new Category III CPT 
      code for EsoCheck cell collection and a proposed ICD-10 diagnosis code 
      for positive EsoGuard results, which will make EsoGuard and EsoCheck 
      easier to bill, track and integrate into clinical practice. 
 
   -- Announced publication of an 11,991-patient real-world EsoGuard study, the 
      largest peer-reviewed study of nonendoscopic esophageal precancer testing 
      to date. Sampling with the EsoCheck(R) Esophageal Cell Collection 
      Device was successful in 95% of patients and averaged less than two 
      minutes. The procedure was well tolerated, with no reported 
      device-related adverse events and consistent performance across operators, 
      including newly trained personnel. 
 
   -- The American Gastroenterological Association (AGA) released its draft 
      Barrett's esophagus guidelines for public comment. The draft names 
      EsoGuard and EsoCheck as an alternative to endoscopy, with high certainty 
      of evidence. EsoGuard is the only commercially available test cited. 
 
   -- Strengthened balance sheet with a $15.0 million private placement to 
      existing long-term investors. 

Financial Results

   -- For the three months ended September 30, 2026, EsoGuard related revenues 
      were $1.2 million. Operating expenses were approximately $13.5 million, 
      which included stock-based compensation expenses of $1.5 million. GAAP 
      net loss attributable to common stockholders was approximately $6.7 
      million, or $(0.03) per common share. 
 
   -- As shown below and for the purpose of illustrating the effect of 
      stock-based compensation and other non-cash income and expenses on the 
      Company's financial results, the Company's non-GAAP adjusted loss for the 
      three months ended September 30, 2026 was approximately $10.6 million or 
      $(0.06) per common share. 
 
   -- Lucid had cash and cash equivalents of $18.0 million as of September 30, 
      2026, compared to $34.7 million as of December 31, 2025. Subsequent to 
      quarter end, Lucid closed a $15.0 million Series C Convertible Preferred 
      Stock financing. 
 
   -- The unaudited financial results for the three and nine months ended 
      September 30, 2026, were filed with the SEC on Form 10-Q on November 12, 
      2026, and available at www.luciddx.com or www.sec.gov. 

Lucid Non-GAAP Measures

   -- To supplement our unaudited financial results presented in accordance 
      with U.S. generally accepted accounting principles (GAAP), management 
      provides certain non-GAAP financial measures of the Company's financial 
      results. These non-GAAP financial measures include net loss before 
      interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP 
      adjusted loss, which further adjusts EBITDA for stock-based compensation 
      expense and other non-cash income and expenses, if any. The foregoing 
      non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not 
      recognized terms under U.S. GAAP. 
 
   -- Non-GAAP financial measures are presented with the intent of providing 
      greater transparency to the information used by us in our financial 
      performance analysis and operational decision-making. We believe these 
      non-GAAP financial measures provide meaningful information to assist 
      investors, shareholders, and other readers of our unaudited financial 
      statements in making comparisons to our historical financial results and 
      analyzing the underlying performance of our results of operations. These 
      non-GAAP financial measures are not intended to be, and should not be, a 
      substitute for, considered superior to, considered separately from, or as 
      an alternative to, the most directly comparable GAAP financial measures. 
 
   -- Non-GAAP financial measures are provided to enhance readers' overall 
      understanding of our current financial results and to provide further 
      information for comparative purposes. Management believes the non-GAAP 
      financial measures provide useful information to management and investors 
      by isolating certain expenses, gains, and losses that may not be 
      indicative of our core operating results and business outlook. 
      Specifically, the non-GAAP financial measures include non-GAAP adjusted 
      loss, and its presentation is intended to help the reader understand the 
      effect of the loss on the issuance or modification of convertible 
      securities, the periodic change in fair value of convertible securities, 
      the loss on debt extinguishment, and the corresponding accounting for 
      non-cash charges on financial performance. In addition, management 
      believes non-GAAP financial measures enhance the comparability of results 
      against prior periods. 
 
   -- A reconciliation to the most directly comparable GAAP measure of all 
      non-GAAP financial measures included in this press release for the three 
      and nine months ended September 30, 2026, and 2025 are as follows: 
 
   (in thousands 
 except per-share      For the three months     For the nine months 
     amounts)          ended September 30,      ended September 30, 
                         2026        2025        2026         2025 
                      ----------  ----------  -----------  ----------- 
 
Revenue                   $1,203      $1,211       $3,932       $3,202 
 
Operating expenses        13,479      12,970       41,122       38,831 
Other (Income) 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment